INTUITUS
12.10.2016 09:09:49 CEST | Business Wire | Press release
The MD of one of Europe’s leading private equity advisers has warned that technology and IT ‘red flags’ could put at risk the exits or re-financings of companies that would otherwise be seeing deals get over the line successfully with international and London-based institutions and corporate investors.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161012005052/en/
While various reports have indicated a surge of interest from foreign investors in UK private-equity-owned assets during the second half of 2016 - partly driven by a sharp drop in the value of the pound - that shows signs of continuing into 2017, forward planning in the twelve months leading up to the exit can have a huge impact not only on deal value but whether the deal concludes.
Fixing technology and IT operations can require considerable time and effort, warns Intuitus MD and founder, Calum Stewart:
“Technology has never been more critical to exit readiness than it is today and our client base consistently tells us that if IT problems are discovered in the lead-up to exit it is often too late to redress the situation before potential buyers start taking a look. Potential issues and deal-breakers include intellectual property disputes, contractual disputes, capacity planning and product development problems.”
“In a typical sale process, any significant technology or IT problem presenting a current or future risk will be likely to delay the process and may also depreciate the value that you’re trying to extract. In the worst instance, it could even derail the sale completely.”
- Intuitus - whose private equity clients include Inflexion, The Carlyle Group, Dunedin, Triton and Scottish Equity Partners - is in on track to advise on over 100 deals during 2016, with approximately 30% of deal activity involving non-UK assets.
- Intuitus offers its private equity and corporate clients commercially-focused, independent technology and IT expertise throughout the full investment life cycle - at the point of acquisition, during ownership and at exit. Supported by a network of internationally-experienced consultants, mainly former CEOs, CTOs, CIOs and IT Directors from a wide range of industry sectors, and managed through the company’s unique, integrated delivery model, the company is targeting expansion in the UK, Benelux, France, Germany and the Nordics in 2017.
- Intuitus won the Specialist Adviser of the Year award at The Private Equity Awards 2016.
Follow Intuitus on LinkedIn and Twitter
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005052/en/
Contact:
Intuitus
Calum Stewart
+44 (0)131 618 0512
or
Freer
Consultancy
Nick Freer
+44 (0)7841 571 871
nick@freerconsultancy.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Integrates AI into Client Portfolios – Informed by Agentic Technology, Controlled by the Client1.6.2026 16:00:00 CEST | Press release
Clients Can Research Stocks, Analyze Performance, and Generate Trade Instructions in Claude. The Client Approves Every Trade. Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced agentic trading through direct integration with Claude, one of the world's leading AI platforms. Available through the AI platform’s certified connector marketplace, the integration lets clients manage their accounts and access more than 170 global markets. "Interactive Brokers has used technology for over four decades to help investors make more informed decisions and interact more efficiently with markets," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Investors are increasingly using artificial intelligence to research markets, analyze information and generate ideas. We believe the next logical step is to allow clients to securely connect AI tools directly to their brokerage accounts — whether they want a simple conversational interface, deeper portfolio analy
AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 15:01:00 CEST | Press release
AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-
Seoul Semiconductor's World-First 'HV Opto-Semiconductor' Powers Up Global Top 4 Automakers1.6.2026 15:00:00 CEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world's first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world's top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/ Comparison: Conventional 3V LED vs. Seoul Semiconductor 12V 'HV Opto-Semiconductor' (Figure: Seoul Semiconductor) The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplific
Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync™ Series OSA 55101.6.2026 14:00:00 CEST | Press release
News summary: Defense operations require resilient timing architectures that maintain synchronization in contested and GNSS-denied environments ruggedSync™ Series OSA 5510 delivers assured timing and extended holdover in a MIL-qualified platform for tactical, deployable operations Zero-trust resiliency with diversified cPNT sources, including M-Code, PRS and STL, strengthens operational continuity for defense communications, navigation and mission-critical infrastructure Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS suppor
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy1.6.2026 14:00:00 CEST | Press release
- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise. “The Phase 3 RAINIER trial is the largest conducted in IgAN and achieved full enrollment faster than any contemporary IgAN trial, reflecting the significant unmet need in IgAN and our urgency to bring povetacicept to patients with this serious disease,” said Nia Tatsis, Ph.D., Executi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
